Table 5.
Outcomes of eyes with NPDR or PDR
| Outcomes | non-DME | DME | ||||
|---|---|---|---|---|---|---|
| NPDR | PDR | P value | NPDR | PDR | P value | |
| Improvement in DRSS levels, n (%) | ||||||
| ≥ 2 steps | 1 | 2 | 1.000 | 20 | 4 | 0.003** |
| < 2 steps | 4 | 8 | 9 | 13 | ||
| BCVA change, M (P25, P75), logMAR | 0.0 (0.0–0.0) | 0.0 (0.0–0.1) | 0.358 | 0.0 (-0.3–0.0) | 0.0 (-0.1–0.5) | 0.068 |
| CMT change, M (P25, P75), μm | 76 (-7.5–143.8) | 2.0 (-1.5–22.5) | 0.642 | -19.5 (-117.0–87.8) | 29.5 (-63.3–80.5) | 0.319 |
| Number of anti-VEGF injections, M (P25, P75) | 1.0 (1.0–1.5) | 2.0 (1.0–2.3) | 0.135 | 3.0 (2.0–5.0) | 3.0 (2.0–4.0) | 0.474 |
| Presence of adverse events, n (%) | 2 (40) | 4 (40) | 1.000 | 0 (0) | 8 (47.1) | < 0.001*** |
DME diabetic macular edema, NPDR nonproliferative diabetic retinopathy, PDR proliferative diabetic retinopathy, DRSS diabetic retinopathy severity scale, BCVA best-corrected visual acuity, CMT central macular thickness
* P < 0.05; **P < 0.01; *** P < 0.001